The main mode of action of L-NAME was its capacity to activate DC and to reduce Treg accumulation in tumor beds, thereby increasing the CD8+/FOXP3 ratio in the context of a long-term PD-1 blockade. This evidence concerns the gene FOXP3 and neoplasm.